News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2016

Epigenomics AG Announces 2016 First Quarter Financial Results and Reports on Operational Highlights

PDF 214 KB 23.05.2016 Berlin (Germany) and Germantown, MD (U.S.A.), May 23, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first quarter 2016 ending March 31. “During the first quarter 2016, our main efforts were focused on the final steps towards […]

Read more

LabCorp is First U.S. Laboratory Network to Offer Epigenomics’ Epi pro Colon® Colorectal Cancer Screening Test, Nationally Available Immediately

PDF 150 KB 09.05.2016 Berlin (Germany) and Germantown, MD (U.S.A.), May 9, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced that Laboratory Corporation of America® Holdings (LabCorp®) is the first laboratory network in the U.S. to offer Epi proColon®, a blood-based test for colorectal cancer screening. Epi […]

Read more

China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015

PDF 149 KB 02.05.2016 Only 9 out of 7530 approved medical devices in 2015 were named “innovative medical product” by the Chinese regulators Epigenomics innovative blood-based Septin9 test Epi proColon® for early detection of colorectal cancer (CRC) is approved in the U.S., China and Europe CRC is a rapidly growing medical problem in China, about 290 […]

Read more

Epigenomics announces commercial launch of Epi proColon® in the U.S.

PDF 544 KB 27.04.2016 Berlin (Germany) and Germantown, MD (U.S.A.), April 26, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that Epi proColon®, its blood-based test for colorectal cancer screening, has now been made commercially available in the U.S. under a joint commercialization agreement with […]

Read more

Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016

PDF 224 KB   Berlin (Germany) and Germantown, MD (U.S.A.), April 18, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will present data from a validation study with a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer at the Annual Meeting 2016 of […]

Read more

Epigenomics receives FDA approval for Epi proColon®

PDF 547 KB 13.04.2016 First and only blood-based colorectal cancer screening test approved by the FDA  Innovative, convenient and effective screening option for millions of eligible Americans  Commercialization initiated with partner Polymedco    Berlin (Germany) and Germantown, MD (U.S.A.), April 13, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics […]

Read more